Weekly epidemiological recordRelevé épidémiologique hebdomadaire 3 MAY 2024, 99th YEAR / 3 MAI 2024, 99e ANNÉE
No 18, 2024, 99, 203–224
The WHO position papers are concerned primarily with the use of vaccines in large-scale vaccination programmes.
The position papers are intended for use by... national public health officials and managers of immunization programmes.
This paper focuses on the second licensed dengue vaccine, TAK-003 (Qdenga, Takeda), along with WHO’s position for its use, and provides an update on the first licensed dengue vaccine, CYD-TDV.
more
Weekly Epidemiological Record (WER), 17 September 2021, Vol. 96, No. 37 (pp. 445-460)
Review
Drake AL et al. Journal of the International AIDS Society 2019, 22:e25271 http://onlinelibrary.wiley.com/doi/10.1002/jia2.25271/full | https://doi.org/10.1002/jia2.25271
Eradication of yaws in India | Éradication du pian en Inde - 17 April 2015, 90th Year / 17 Avril 2015, 90e Année | No. 16, 2015, 90, 161–168 | http://www.who.int/wer
Coordinated Use of Anthelminthic Drugs in Control Interventions: a Manual for Health Professionals and Programme Managers
Yaws is a disfiguring non-venereal disease caused by infection with the spirochaete. Treponema pallidum subspecies pertenue which is closely related to the causative agent of syphilis and those of the other endemic treponematoses, bejel and pinta. The disease is endemic in certain areas of the World... Health Organization (WHO) African, South-East Asia and Western Pacific regions. Of the neglected tropical diseases identified for elimination and eradication, yaws is one of two diseases targeted for eradication. In 1949, the Second World Health Assembly adopted resolution WHA2.36, which addresses yaws, bejel and pinta as major public health problems that need attention.
more
This document provides guidance for countries on how to implement activities to achieve the interruption of yaws transmission. It is intended for use by national yaws eradication programmes, partners involved in the implementation of yaws eradication activities and WHO technical staff who provide te...chnical support to countries in the eradication of yaws.
more
Bull World Health Organ 2015;93:457–467 | doi: http://dx.doi.org/10.2471/BLT.14.147215
Research to develop point-of-care tests is in progress. Treatment of Buruli ulcer comprises 8 weeks of combined antibiotics (rifampicin and clarithromycin). Complementary therapies such as wound care, skin graft and prevention of disability are needed in some cases to ensure full recovery.
The targ...et set by the World Health Organization (WHO) for control of Buruli ulcer is for countries to achieve a rate of case confirmation by PCR of at least 70%. All endemic countries have at least one PCR facility to support confirmation of cases. However, most countries in the WHO African Region have not been able to reach the target, and the rate of case confirmation has been declining
more
This document sets out the criteria and procedures to be followed by countries in verifying the interruption of yaws transmission. It is intended for use by international verification teams, national yaws eradication programmes and WHO technical staff involved in the eradication of yaws.
n October 2019, WHO convened the first meeting of the Buruli ulcer laboratory network (BU-LABNET) in Yaoundé, Cameroon, bringing together 11 laboratories from nine countries at the Pasteur Centre of Cameroon (CPC), the network’s Coordinating Centre. The network was formally established at th...is meeting (1) and its members were those present. The objective of BU LABNET is to improve diagnosis of Buruli ulcer based on polymerase chain reaction (PCR) using standardized testing protocols, involving external quality assurance programmes and sharing knowledge among member laboratories.
more
The aim of the meeting was to broaden the network’s initiatives. Preliminary work involved integrating laboratory testing for skin NTDs other than Buruli ulcer, such as cutaneous leishmaniasis, mycetoma, leprosy and yaws, while extending the network’s reach to encompass additional laboratories.
The 2023 meeting of the WHO Clinical Consortium on Healthy Ageing (CCHA) was the group’s ninth gathering and took place in Geneva 5–7 December 2023. The meeting was structured around seven panels, with a series of technical presentations, plenary discussions and group work, and a final session o...utlining the work programme for 2024.
more